Home › Therapeutic areas › Metabolic › Obesity
Obesity (10 companies)
Companies with an active program in Obesity.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| BMEA | Biomea Fusion | MetabolicOncology | 2 | Phase 2 | $41.1M | 4 |
| ENTX | Entera Bio | GI/HepatologyMetabolic Rare | 1 | Phase 2 | $547M | 4 |
| GUTS | Fractyl Health | Metabolic | 1 | Phase 3 | — | 1 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 1 | Phase 3 | $864M | 16 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 Rare | 3 | Phase 3 | $11.2M | 8 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 3 | Approved | $8.62B | 12 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 10 | Approved | $7.78B | 14 |
| GPCR | Structure Therapeutics | MetabolicRespiratory Rare | 3 | Phase 3 | $4.35B | 5 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 3 | Phase 3 | $3.42B | 9 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 1 | Phase 2 | $665M | 5 |
No companies match.